<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04477603</url>
  </required_header>
  <id_info>
    <org_study_id>TMF-VV-17471</org_study_id>
    <nct_id>NCT04477603</nct_id>
  </id_info>
  <brief_title>Impella ECP Early Feasibility Study</brief_title>
  <acronym>ECP EFS</acronym>
  <official_title>Use of the Impella ECP in Patients Undergoing an Elective High-Risk Percutaneous Coronary Intervention: An Early Feasibility Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abiomed Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Abiomed Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Impella ECP EFS is a prospective, multicenter, single-arm, feasibility study evaluating&#xD;
      the safety of the Impella ECP device in adult patients undergoing an elective high-risk&#xD;
      percutaneous coronary intervention.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective, multicenter, single-arm, feasibility study evaluating the safety of&#xD;
      the Impella ECP device in adult patients undergoing an elective high-risk percutaneous&#xD;
      coronary intervention (HRPCI). Additionally, this study will evaluate the feasibility of&#xD;
      placing the ECP pump across the aortic valve without the use of a guidewire and assess the&#xD;
      ability of the pump to provide sufficient hemodynamic support during a HRPCI. Investigational&#xD;
      device products include: Impella ECP pump system (a percutaneous transvalvular micro-axial&#xD;
      blood pump), 9Fr introducer sheath, and the automated Impella controller with revised console&#xD;
      software to allow control of the Impella ECP.&#xD;
&#xD;
      Following informed consent, subjects eligible for a HRPCI that meet all of the inclusion and&#xD;
      none of the exclusion criteria will be enrolled into the study. The intended coronary&#xD;
      intervention is then carried out under mechanical circulatory support by the Investigational&#xD;
      Device. This device is inserted through a sheath that has been deployed through a femoral&#xD;
      puncture, following crimping of the Impella ECP. After proper placement and wireless passage&#xD;
      of the aortic valve, the device pumps blood from the left ventricle into the aorta. Once the&#xD;
      interventional procedure is completed, the device is weaned and removed. Subjects will be&#xD;
      followed up until 30 days post intervention.&#xD;
&#xD;
      The primary and secondary end points will be summarized and presented without formal&#xD;
      statistical testing. Safety will be assessed by the rate of composite Major Device-Related&#xD;
      Adverse Events, evaluated at the end of the HRPCI procedure. Feasibility is defined as the&#xD;
      successful delivery, initiation and maintenance of sufficient hemodynamic support to increase&#xD;
      in or maintenance the MAP at physiologic levels (&gt; 60 mmHg), evaluated up to the end of&#xD;
      procedure.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 9, 2020</start_date>
  <completion_date type="Anticipated">March 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">February 28, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Device Feasibility</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Feasibility: successful hemodynamic support</measure>
    <time_frame>through end of procedure, 1 day</time_frame>
    <description>The feasibility assessment is defined as the successful delivery, initiation and maintenance of sufficient hemodynamic support to increase in or maintenance the MAP at physiologic levels (&gt; 60 mmHg)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety: Major Device-Related Adverse Events</measure>
    <time_frame>through end of procedure, 1 day</time_frame>
    <description>The rate of composite Major Device-Related Adverse Events</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Technical Success</measure>
    <time_frame>through end of procedure, 1 day</time_frame>
    <description>The ability to complete the entire Impella ECP delivery procedure and pump initiation without device malfunction.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Procedural Success</measure>
    <time_frame>through end of procedure, 1 day</time_frame>
    <description>Technical success with a sufficient flow generation by the pump in order to increase or maintain MAP during the interventional procedure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of each individual Major Device-Related Adverse Event</measure>
    <time_frame>through end of study, 30 days</time_frame>
    <description>The rate of each individual Major Device-Related Adverse Event.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of composite Major Device-Related Adverse Events</measure>
    <time_frame>through end of study, 30 days</time_frame>
    <description>The rate of composite Major Device-Related Adverse Events.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>High-risk Percutaneous Coronary Intervention</condition>
  <arm_group>
    <arm_group_label>Subjects receiving the Impella ECP</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Impella ECP</intervention_name>
    <description>Subjects will receive the Impella ECP prior to high-risk percutaneous intervention. Device escalation or early termination of the study will be allowed for subjects as deemed necessary by the treating physician. Subjects will be followed until 30-days post-intervention.</description>
    <arm_group_label>Subjects receiving the Impella ECP</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age ≥ 18 years and &lt;80 years&#xD;
&#xD;
          2. Subject has signed the informed consent&#xD;
&#xD;
          3. Scheduled for an elective high risk percutaneous coronary intervention with&#xD;
             hemodynamic support&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Aortic valve disease that is anticipated to be prohibitive to Impella ECP crossing,&#xD;
             including greater than mild aortic stenosis&#xD;
&#xD;
          2. Previous aortic valve replacement or reconstruction&#xD;
&#xD;
          3. Thrombus in the left atrium or ventricle&#xD;
&#xD;
          4. ECMO or any other mechanical circulatory support within the past 7 days&#xD;
&#xD;
          5. Patients with known aortic diseases like aortic dissection, Marfan-Syndrome, Morbus&#xD;
             Erdheim-Gsell or others&#xD;
&#xD;
          6. Any contraindication or inability to place an Impella® including tortuous vascular&#xD;
             anatomy, femoral bruits or absent pedal pulses&#xD;
&#xD;
          7. Irreversible brain disorders as a result of a preexisting* cerebral disease&#xD;
&#xD;
          8. Cardiogenic shock or acutely decompensated preexisting chronic heart failure and/or&#xD;
             pre-procedure use of inotropic or vasopressor support&#xD;
&#xD;
          9. Infection of the proposed procedural access site or suspected systemic active&#xD;
             infection, including any fever.&#xD;
&#xD;
         10. Known contraindication to heparin, pork, pork products, contrast media or study&#xD;
             required medication(s) (i.e. Aspirin, heparin)&#xD;
&#xD;
         11. Known coagulopathy&#xD;
&#xD;
         12. History of heparin induced thrombocytopenia (HIT)&#xD;
&#xD;
         13. Known hemoglobin diseases, such as sickle cell anemia or thalassemia&#xD;
&#xD;
         14. Suspected or known pregnancy or lactating women&#xD;
&#xD;
         15. Subject has other medical, social, or psychological problems that, in the opinion of&#xD;
             the Investigator, compromises the subject's ability to give written informed consent&#xD;
             and/or to comply with study procedures&#xD;
&#xD;
         16. Participation in the active treatment or follow-up phase of another clinical study of&#xD;
             an investigational drug or device which has not reached its primary end point&#xD;
&#xD;
         17. Subject belongs to a vulnerable population [Vulnerable subject populations are defined&#xD;
             as individuals with mental disability, persons in nursing homes, children,&#xD;
             impoverished persons, homeless persons, nomads, refugees, and those permanently&#xD;
             incapable of giving informed consent. Vulnerable populations also may include members&#xD;
             of a group with a hierarchical structure such as university students, subordinate&#xD;
             hospital and laboratory personnel, employees of the Sponsor, members of the armed&#xD;
             forces, and persons kept in detention].&#xD;
&#xD;
               -  Preexisting is used to describe a status of the patient that existed before&#xD;
                  patient enrollment.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>79 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chuck Simonton, MD</last_name>
    <role>Study Director</role>
    <affiliation>Abiomed Inc.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Duane Pinto, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beth Israel Deaconess Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Seth Bilazarian, MD</last_name>
    <role>Study Director</role>
    <affiliation>Abiomed Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Salima Reddy, MPH</last_name>
    <phone>817-360-3948</phone>
    <email>sreddy@abiomed.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Rachel Bostonian</last_name>
    <phone>978-882-8229</phone>
    <email>rbostonian@abiomed.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Tufts Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02111</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vilma Castaneda, MD</last_name>
      <phone>617-636-7537</phone>
      <email>vcastaneda@tuftsmedicalcenter.org</email>
    </contact>
    <investigator>
      <last_name>Navin Kapur, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Andrew Weintraub, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pankaj Jain, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Michael Salama, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Carey Kimmelstiel, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Charles Resor, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ayan Patel, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Henry Ford Hospital</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Margaret Fox</last_name>
      <phone>313-916-1879</phone>
      <email>mfox2@hfhs.org</email>
    </contact>
    <investigator>
      <last_name>William O'Neill, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Brian O'Neill, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mir Basir, DO</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Khaldoon Alaswad, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ascension St. John Hospital</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48236</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Renee Bess</last_name>
      <phone>313-343-4811</phone>
      <email>renee.bess@ascension.org</email>
    </contact>
    <investigator>
      <last_name>Amir Kaki, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Theodore Schreiber, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Christ Hospital</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Darlene Rock, RN, MBA</last_name>
      <phone>513-585-1766</phone>
      <email>Darlene.Rock@thechristhospital.com</email>
    </contact>
    <investigator>
      <last_name>Timothy Smith, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>James Kong, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Robert Riley, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Steven Rudick, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>July 13, 2020</study_first_submitted>
  <study_first_submitted_qc>July 17, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 20, 2020</study_first_posted>
  <last_update_submitted>October 14, 2021</last_update_submitted>
  <last_update_submitted_qc>October 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HRPCI</keyword>
  <keyword>High-risk percutaneous coronary intervention</keyword>
  <keyword>circulatory support</keyword>
  <keyword>left ventricular unloading</keyword>
  <keyword>Abiomed</keyword>
  <keyword>Impella</keyword>
  <keyword>Impella ECP</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

